Of note, a similar selective PDE4B inhibitor, nerandomilast, is currently evaluated in a phase 3 trial in patients with IPF (clinicalTrials.gov ID NCT05321069). This evidence concerns the gene PDE4B and idiopathic pulmonary fibrosis.